Hypertrophic cardiomyopathy medical therapy: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing [[heart failure]] management, maintaining [[normal sinus rhythm]], rate control and anticoagulation in the presence of [[atrial fibrillation]], and implantation of an [[automatic implantable cardiac defibrillator]] in those patients who survive [[sudden cardiac death]]. | The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing [[heart failure]] management, maintaining [[normal sinus rhythm]], rate control and anticoagulation in the presence of [[atrial fibrillation]], and implantation of an [[automatic implantable cardiac defibrillator]] in those patients who survive [[sudden cardiac death]]. | ||
One of the funadamental goals of treatment is to relieve disabling [[dyspnea]] and improve exercise tolerance. It should be noted that the majority of patients do not have [[outflow tract obstruction]], and therefore would not benefit from surgery. Medical therapy is therefore a mainstay of treatment. | |||
==Diuretics== | ==Diuretics== | ||
Revision as of 01:03, 13 August 2011
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy medical therapy On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy medical therapy |
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing heart failure management, maintaining normal sinus rhythm, rate control and anticoagulation in the presence of atrial fibrillation, and implantation of an automatic implantable cardiac defibrillator in those patients who survive sudden cardiac death.
One of the funadamental goals of treatment is to relieve disabling dyspnea and improve exercise tolerance. It should be noted that the majority of patients do not have outflow tract obstruction, and therefore would not benefit from surgery. Medical therapy is therefore a mainstay of treatment.
Diuretics
Treatment with diuretics (a mainstay of CHF treatment) will exacerbate symptoms in hypertrophic cardiomyopathy by decreasing ventricular volume and increasing outflow resistance.